Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Annual Information Update

3 Mar 2009 17:26

RNS Number : 2583O
Phytopharm PLC
03 March 2009
 



Phytopharm plc

Annual Information Update

Phytopharm plc (the Company) announces that, in accordance with the requirements of Prospectus Rule 5.2 issued by the Financial Services Authority, and following publication of the Annual Report on 28 January 2009, the following information has been published or made available to the public between 3 February 2008 and 3 March 2009 inclusive, in compliance with laws and rules dealing with the regulation of securities, issuers of securities and securities markets.

For the purpose of this update, only references to the information are provided. Full copies of each item can be found at the locations specified below. In accordance with the provisions of Article 27.3 of the Prospectus Directive Regulations, we confirm that to the best of our knowledge, information relating to 'Holdings in Company' and 'Director/PDMR Shareholdings' is up to date at the date of this announcement, but it is acknowledged that such disclosures may, at any time, become out of date, due to changing circumstances.

1. Announcements made via Regulatory Information Services

All documents listed below were published via a regulatory information service on the dates indicated

Date of publication

Title

5 February 2008

Total voting rights

14 February 2008

Director / PDMR shareholding

18 February 2008

Interim management statement

28 February 2008 

Notice of AGM

3 March 2008

Total voting rights

4 March 2008 

Publication of prospectus

13 March 2008 

Director / PDMR shareholding

25 March 2008 

Placing and open offer

27 March 2008 

Result of AGM

27 March 2008 

Result of AGM

28 March 2008 

Director / PDMR shareholding

28 March 2008 

Director / PDMR shareholding

28 March 2008 

Director / PDMR shareholding

28 March 2008 

Director / PDMR shareholding

28 March 2008 

Director / PDMR shareholding

28 March 2008 

Director / PDMR shareholding

28 March 2008 

Director / PDMR shareholding

28 March 2008 

Holdings in Company

1 April 2008 

Total voting rights

2 April 2008

Holdings in Company

4 April 2008 

Holdings in Company

4 April 2008 

Holdings in Company

4 April 2008 

Holdings in Company

4 April 2008 

Holdings in Company

4 April 2008 

Holdings in Company

4 April 2008 

Holdings in Company

4 April 2008 

Holdings in Company

9 April 2008 

Holdings in Company

14 April 2008 

Holdings in Company

14 April 2008 

Holdings in Company

14 April 2008 

Director / PDMR shareholding

1 May 2008

Total voting rights

2 May 2008

Block listing review

12 May 2008

Director / PDMR shareholding

16 May 2008

Notice of interim results

21 May 2008

Myogane™ granted EU Orphan drug status

29 May 2008

Interim results

3 June 2008

Director / PDMR shareholding

3 June 2008

Director / PDMR shareholding

4 June 2008

Total voting rights

11 June 2008

Product launch

13 June 2008

Director / PDMR shareholding

3 July 2008

Interim management statement

9 July 2008

Director / PDMR shareholding

21 July 2008

Price monitoring extension

8 August 2008

Director / PDMR shareholding

10 September 2008

Director / PDMR shareholding

9 October 2008

Director / PDMR shareholding

5 November 2008

Block listing interim review

11 November 2008

Director / PDMR shareholding

13 November 2008

Board change

14 November 2008

Trading statement

27 November 2008

Final results

12 December 2008

Portfolio update

19 December 2008

Price monitoring extension

19 December 2008

Second price monitoring extension

28 January 2009

Annual report and accounts & notice of AGM

17 February 2009

Interim management statement

17 February 2009

Holdings in Company

19 February 2009 

Holdings in Company

2. Documents published or sent to Shareholders or filed with the UK Listing Authority or submitted to the FSA

 

Date of publication

Title

28 February 2008 

Notice of AGM

28 February 2008 

Prospectus and notice of EGM

28 February 2008 

Form 1 Application for admission of securities to trading

28 February 2008 

Application for admission of securities to the Official List

28 March 2008 

Special resolutions passed at AGM

28 March 2008 

Special resolutions passed at EGM

29 January 2009

Annual report 2008

29 January 2009

Notice of AGM

Certain documents submitted to the FSA can be viewed at the Document Viewing Facility situated at the Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS

The 2008 Interim and 2008 Annual reports are also available on the Company's website www.phytopharm.com

3. Documents filed at Companies House

The Company has submitted the following filings to Companies House:

Date of Publications

Title

14 January 2008 

Form 363 Annual Return

24 January 2008

Form 88(2) Return of Allotments of Shares

13 February 2008

Form 88(2) Return of Allotments of Shares

13 March 2008

Form 88(2) Return of Allotments of Shares

28 March 2008 

Special resolutions passed at AGM

28 March 2008 

Special resolution passed at EGM

28 March 2008 

Form 123 Notice of Increase in Nominal Capital

28 March 2008

Articles of Association

2 April 2008 

Form 88(2) Return of Allotments of Shares

14 April 2008

Form 88(2) Return of Allotments of Shares

13 May 2008

Form 88(2) Return of Allotment of Shares

2 July 2008

Form 288b Terminating appointment of Company Secretary

2 July 2008

Form 288a Appointment of Company Secretary

14 November 2008

Form 288b Terminating appointment of Director - Dr D Rees

14 November 2008

288b Terminating appointment of Director - Mr P Morgan

10 December 2008

Form 363 Annual Return

21 January 2009

Form 353a Notice of place for inspection of a register of members

29 January 2009

Annual report and accounts for the year ended 30 September 2008

Copies of these documents can be obtained from Companies House, Crown WayCardiff CF14 3UZ (Telephone 0870 3333 636, email at enquiries @companies-house.gov.uk) or, if you are a registered user, through Companies House Direct at www.companies-house.gov.uk

Copies of all documents referred to above are also available for inspection at the Company's registered office (Corpus Christi House, 9 West Street, Godmanchester, Cambs PE29 2HYUnited Kingdom) during normal business hours or by request from the Company Secretary.

For further information, please contact:

Zoe McGowan, Head of Finance

Phytopharm plc Tel No: +44 (0)1480 437697

Further information about Phytopharm can be found on the Company's website www.phytopharm.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AIUEAKDDESFNEFE
Date   Source Headline
25th May 20217:00 amRNSHalf yearly report to 31 March 2021
20th May 20217:00 amRNSPhase II Alzheimer’s disease contract award
19th May 20217:00 amRNSContract win for new neuroinflammatory disorder
11th May 20217:00 amRNSNotice of results
28th Apr 20217:00 amRNSContract win for new stroke study
26th Apr 20217:00 amRNSTrading update
19th Apr 20218:21 amRNSHolding(s) in Company
12th Apr 20214:00 pmRNSHolding(s) in Company
12th Apr 20217:00 amRNSInvestment in Ixico plc
1st Apr 20217:00 amRNSHolding(s) in Company
25th Mar 20219:14 amRNSPDMR Transaction
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
23rd Mar 20214:40 pmRNSSecond Price Monitoring Extn
23rd Mar 20214:35 pmRNSPrice Monitoring Extension
23rd Mar 20213:05 pmRNSHuntington’s disease Phase III contract updates
15th Mar 20214:41 pmRNSSecond Price Monitoring Extn
15th Mar 20214:35 pmRNSPrice Monitoring Extension
15th Mar 20212:06 pmRNSSecond Price Monitoring Extn
15th Mar 20212:00 pmRNSPrice Monitoring Extension
15th Mar 202111:06 amRNSSecond Price Monitoring Extn
15th Mar 202111:01 amRNSPrice Monitoring Extension
15th Mar 20217:00 amRNSCollaboration with Microsoft
10th Mar 20217:00 amRNSIXICO chosen for new Phase II AD study
2nd Mar 20217:00 amRNSIXICO selected by Cyclerion for a new AD study
1st Mar 20215:25 pmRNSExercise of Options; PDMR Dealing
1st Mar 20217:00 amRNSConference attendance and presentations
29th Jan 202110:19 amRNSPDMR Dealing
21st Jan 202111:05 amRNSResult of AGM
7th Jan 20217:00 amRNSIssue of Equity
24th Dec 20207:00 amRNSIXICO secures new contract for £3.4 million
14th Dec 202011:54 amRNSHolding(s) in Company
8th Dec 20207:00 amRNSIXICO contract with new large global pharma
3rd Dec 20202:06 pmRNSSecond Price Monitoring Extn
3rd Dec 20202:01 pmRNSPrice Monitoring Extension
2nd Dec 20207:00 amRNSFinancial Results for the year ended 30 Sept 2020
27th Nov 20207:00 amRNSIXICO announces £1.9 million new study award
9th Nov 20207:00 amRNSNotice of Results
3rd Nov 20207:00 amRNSAdditional Alzheimer’s disease contracts
22nd Oct 20207:00 amRNSFurther Huntington’s disease contracts
19th Oct 20207:00 amRNSIXICO to Present at SCA & ARCA Global Conference
19th Oct 20207:00 amRNSTrading Update for year ended 30 September 2020
16th Oct 20207:00 amRNSIXICO and NYU Langone Health sign agreement
30th Sep 20202:05 pmRNSSecond Price Monitoring Extn
30th Sep 20202:00 pmRNSPrice Monitoring Extension
29th Sep 20207:00 amRNS>£2m contract extension win - Huntington’s disease
24th Sep 20207:00 amRNSCollaboration with TRACK-FA NeuroimagingConsortium
21st Sep 20207:00 amRNSIXICO selected to support Alzheimer’s trial
11th Sep 202010:36 amRNSHolding(s) in Company
26th Aug 202011:55 amRNSInvestor presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.